<?xml version="1.0" ?>
<document id="f02529d9be6c7576b60d295c4e04d15a9a432614">
  <chunk id="f02529d9be6c7576b60d295c4e04d15a9a432614.c0" text="The C-Terminal Sequence of IFITM1 Regulates Its Anti-HIV-1 Activity"/>
  <chunk id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1" text="The interferon-inducible transmembrane (IFITM) proteins inhibit a wide range of viruses. We previously reported the inhibition of human immunodeficiency virus type 1 (HIV-1) strain BH10 by human IFITM1, 2 and 3. It is unknown whether other HIV-1 strains are similarly inhibited by IFITMs and whether there exists viral countermeasure to overcome IFITM inhibition. We report here that the HIV-1 NL4-3 strain (HIV-1 NL4-3 ) is not restricted by IFITM1 and its viral envelope glycoprotein is partly responsible for this insensitivity. However, HIV-1 NL4-3 is profoundly inhibited by an IFITM1 mutant, known as Δ(117-125), which is deleted of 9 amino acids at the C-terminus. In contrast to the wild type IFITM1, which does not affect HIV-1 entry, the Δ(117-125) mutant diminishes HIV-1 NL4-3 entry by 3-fold. This inhibition correlates with the predominant localization of Δ(117-125) to the plasma membrane where HIV-1 entry occurs. In spite of strong conservation of IFITM1 among most species, mouse IFITM1 is 19 amino acids shorter at its C-terminus as compared to human IFITM1 and, like the human IFITM1 mutant Δ(117-125), mouse IFITM1 also inhibits HIV-1 entry. This is the first report illustrating the role of viral envelope protein in overcoming IFITM1 restriction. The results also demonstrate the importance of the C-terminal region of IFITM1 in modulating the antiviral function through controlling protein subcellular localization.">
    <entity charOffset="47-55" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e0" ontology_id="CHEBI_36080" text="proteins" type="chemical"/>
    <entity charOffset="473-485" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e1" ontology_id="CHEBI_17089" text="glycoprotein" type="chemical"/>
    <entity charOffset="641-646" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e2" ontology_id="CHEBI_46882" text="amino" type="chemical"/>
    <entity charOffset="641-652" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e3" ontology_id="CHEBI_33704" text="amino acids" type="chemical"/>
    <entity charOffset="647-652" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e4" ontology_id="CHEBI_37527" text="acids" type="chemical"/>
    <entity charOffset="1011-1016" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e5" ontology_id="CHEBI_46882" text="amino" type="chemical"/>
    <entity charOffset="1011-1022" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e6" ontology_id="CHEBI_33704" text="amino acids" type="chemical"/>
    <entity charOffset="1017-1022" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e7" ontology_id="CHEBI_37527" text="acids" type="chemical"/>
    <entity charOffset="1205-1209" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e8" ontology_id="CHEBI_50906" text="role" type="chemical"/>
    <entity charOffset="1228-1235" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e9" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="1367-1376" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e10" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="1406-1413" id="f02529d9be6c7576b60d295c4e04d15a9a432614.c1.e11" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
  </chunk>
</document>
